Here, spectral shift analysis was further evaluated by measuring and quantifying the interaction between the small molecule inhibitor BAY-876 and the GLUT1 transmembrane protein, which is a promising drug target for cancer treatment.35 Due to the presence of a C-terminal His9-tag, DDM-solubilized GLUT1 can be labeled with the Protein Labeling Kit RED-tris-NTA 2nd Generation (cat# MO-L018; NanoTemper Technologies GmbH). This evidence concerns the gene SLC2A1 and cancer.